ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Group PLC Sale and leaseback of building owned by Omega GmbH (3275K)

06/07/2017 11:56am

UK Regulatory


Omega Diagnostics (LSE:ODX)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Omega Diagnostics Charts.

TIDMODX

RNS Number : 3275K

Omega Diagnostics Group PLC

06 July 2017

Omega Diagnostics Group PLC

("Omega" or the "Company")

Sale and leaseback of the building owned by Omega GmbH

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has concluded the sale and leaseback of the building owned by its wholly owned subsidiary, Omega Diagnostics GmbH.

The Company will receive gross proceeds of EUR800,000 and has simultaneously entered into a contract with the new landlord to lease the facility back over 15 years. A rent deposit of just under EUR100,000 will be retained by the landlord initially but which will reduce in stages of five-year periods.

As announced last week, the Company is proposing to raise funds from new and existing shareholders via a placing and open offer, subject to shareholder approval which will be sought at the General Meeting on 18 July 2017. The proceeds from the building sale will be used by the Company for its accelerated growth strategy as outlined in the circular sent to shareholders on 30 June 2017.

Kieron Harbinson, Chief Financial Officer of the Company commented: "We are pleased to be able to supplement our proposed fundraising from the placing and open offer with the sale proceeds from this property transaction. The timing makes good sense as we embark on our accelerated growth strategy and given where the current euro/pound exchange rate sits."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

 
 Omega Diagnostics Group                             Tel: 01259 763 030 
  PLC 
 Andrew Shepherd, Chief                        www.omegadiagnostics.com 
  Executive 
 Kieron Harbinson, Group 
  Finance Director 
 Jag Grewal, Group Sales 
  and Marketing Director 
 
 finnCap Ltd                                         Tel: 020 7220 0500 
 Geoff Nash/James Thompson 
  (Corporate Finance) 
 Mia Gardner (Corporate 
  Broking) 
 
 Walbrook PR Limited         Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                        Mob: 07980 541 893 
 Lianne Cawthorne                                    Mob: 07584 391 303 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DISRFMMTMBAMBIR

(END) Dow Jones Newswires

July 06, 2017 06:56 ET (10:56 GMT)

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Your Recent History

Delayed Upgrade Clock